T cell intrinsic factors including the CD4/CD8 ratio, memory phenotype, expression of exhaustion markers, and metabolic profile can inform how the cells are supported in the lab during CAR manufacture. Standard assessments of CAR T cell function such as cytokine release and polyfunctional index will be important for comparison across trials. Leukemia intrinsic factors such as driver lesion (cytogenetic, fusion, or mutation), preexisting antigen-low clones, and overall antigen burden will inform relapse risk. After infusion, patient monitoring with CAR T cell proliferation area under the curve (AUC), duration of BCA, and assessment with ultrasensitive next-generation sequencing (NGS) MRD will inform the ultimate decision for post–CAR consolidation, such as use of allogeneic transplantation.